Profile cover photo
Profile photo
Cidara Therapeutics
6 followers -
Cidara (NASDAQ: CDTX) is a biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives.
Cidara (NASDAQ: CDTX) is a biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives.

6 followers
About
Posts

Post has attachment
Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results
Add a comment...

Post has attachment
Data from preclinical studies of Cidara's lead antifungal rezafungin will be presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Madrid, Spain, April 21-24. Cidara will present one poster presentation along with four oral presentations, including three that will highlight new data demonstrating activity of rezafungin against Candida auris and azole-resistant Aspergillus. For more information on Cidara's five ECCMID presentations visit:
Add a comment...

Post has attachment
Cidara Therapeutics Provides Clinical Data Updates For Its Lead Antifungal Rezafungin
Add a comment...

Post has attachment
Our CEO Jeffrey Stein, Ph.D., comments on the Company's positive topline results from the Ph 2 STRIVE trial of lead antifungal candidate rezafungin acetate:
Photo
Add a comment...

Post has attachment
Cidara's Phase 2 STRIVE trial of its lead antifungal candidate rezafungin acetate met all of its primary objectives providing evidence of favorable safety, tolerability, and efficacy profile observed in patients with candidemia and/or invasive candidiasis. These positive results from STRIVE enable Cidara to advance its planned Phase 3 pivotal trials in the treatment of candidemia and invasive candidiasis and the prevention (prophylaxis) of invasive fungal infections in mid-2018. The Company will host a conference call and live audio webcast this morning at 8:00 a.m. ET. Read the full release for details:
Add a comment...

Post has attachment
Cidara will present data at the 44th Annual Meeting of The European Society of Blood and Marrow Transplantation on March 18-21. The data presented will highlight the potential of rezafungin acetate for the treatment and prevention of life-threatening invasive fungal infections. For presentation details:
Add a comment...

Post has attachment
Cidara has appointed Chrysa Mineo to the company's board of directors. Ms. Mineo has more than 25 years of operational experience in biopharmaceutical drug development, with strategic leadership roles at leading public biotechnology companies. “Chrysa brings to Cidara a wealth of experience and a track record of success in the biopharmaceutical industry,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “In particular, we expect that her operational business development experience will be of tremendous value as we approach proof-of-concept clinical data for rezafungin and key preclinical data for our Cloudbreak ADC program.”
Add a comment...

Post has attachment
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results
Add a comment...

Post has attachment
Cidara will present at the 8th Advances Against Aspergillosis Conference in Lisbon, Portugal from February 1-3 and at the 2018 BMT Tandem Meetings in Salt Lake City, Utah from February 21-25. A total of four posters will present data from preclinical studies highlighting the potential advantages of rezafungin for the treatment and prevention of invasive fungal infections in immunocompromised patients. For details please visit:
Add a comment...

Post has attachment
Cidara has announced that a newly published Journal of Antimicrobial Chemotherapy supplement provides insights into the future of echinocandin therapy for invasive fungal infections. The supplement, titled "The Future of Echinocandin Therapy", is comprised of nine papers authored by European and North American experts and highlights how new options can be used to augment antifungal treatment and prophylaxis strategies. For details please visit:
Add a comment...
Wait while more posts are being loaded